Cargando…

Surgical treatment of tertiary hyperparathyroidism: does one fit for all?

BACKGROUND: Tertiary hyperparathyroidism (3HPT) is defined as a condition of excessive autonomous excretion of intact parathyroid hormone (iPTH) with persistent hypercalcemia (>10.5 mg/dL) that lasts for more than 12 months after a successful kidney transplantation, in the context of a long cours...

Descripción completa

Detalles Bibliográficos
Autores principales: Casella, Claudio, Guarneri, Claudio, Campanile, Manuela, Adhoute, Xavier, Gelera, Pier Paolo, Morandi, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652876/
https://www.ncbi.nlm.nih.gov/pubmed/38027172
http://dx.doi.org/10.3389/fendo.2023.1226917
_version_ 1785136309733425152
author Casella, Claudio
Guarneri, Claudio
Campanile, Manuela
Adhoute, Xavier
Gelera, Pier Paolo
Morandi, Riccardo
author_facet Casella, Claudio
Guarneri, Claudio
Campanile, Manuela
Adhoute, Xavier
Gelera, Pier Paolo
Morandi, Riccardo
author_sort Casella, Claudio
collection PubMed
description BACKGROUND: Tertiary hyperparathyroidism (3HPT) is defined as a condition of excessive autonomous excretion of intact parathyroid hormone (iPTH) with persistent hypercalcemia (>10.5 mg/dL) that lasts for more than 12 months after a successful kidney transplantation, in the context of a long course secondary hyperparathyroidism (2HPT). The chronic high levels of iPTH cause a worsening of graft function, accompanied by systemic symptoms of hypercalcemia. The only curative therapy is parathyroidectomy (PTX). It remains unclear whether total parathyroidectomy with autotransplantation (TPTX-AT) or subtotal parathyroidectomy (SPTX) lead to better outcomes. AIMS: The aim of this retrospective, single-institution cohort study is to evaluate the rate of persistent or recurrent disease and postoperative calcium/iPTH disturbances in patients treated with TPTX-AT or SPTX for 3HPT. METHODS: A single-center retrospective analysis of 3HPT patients submitted to TPTX-AT or SPTX between 2007–2020 with at least 24 months follow-up was conducted. The outcome parameters included persistence/recurrence of disease, incidence of transitory hypocalcemia, and temporary/permanent hypoparathyroidism. RESULTS: A cohort of 52 patients was analyzed and divided in two groups: 38 (73%) were submitted for TPTX-AT, and 14 patients (27%) were submitted for SPTX. The TPTX-AT population showed lower plasmatic calcium concentrations compared with the SPTX group during the entire follow-up period (p<0.001). There were eight cases (21%) of transitory hypocalcemia in the TPTX-AT group and none in the SPTX group, with p=0.065. Two cases (5%) of temporary hypoparathyroidism occurred in the TPTX-AT group and none in the SPTX group, with p= 0.530. There were no cases of permanent hypoparathyroidism and no cases of persistent disease. No statistical difference was assessed for the recurrence of 3HPT between the TPTX-AT group and the SPTX group (N=1, 3% vs N=1, 7%) (p=0.470). CONCLUSION: No significative difference was registered between the TPTX-AT and SPTX groups in terms of persistence/recurrence of disease, incidence of transitory hypocalcemia, and temporary/permanent hypoparathyroidism. Mean calcium levels iPTH values were statistically lower among the TPTX-AT group compared with the SPTX group while remaining always in the range of normality.
format Online
Article
Text
id pubmed-10652876
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106528762023-01-01 Surgical treatment of tertiary hyperparathyroidism: does one fit for all? Casella, Claudio Guarneri, Claudio Campanile, Manuela Adhoute, Xavier Gelera, Pier Paolo Morandi, Riccardo Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Tertiary hyperparathyroidism (3HPT) is defined as a condition of excessive autonomous excretion of intact parathyroid hormone (iPTH) with persistent hypercalcemia (>10.5 mg/dL) that lasts for more than 12 months after a successful kidney transplantation, in the context of a long course secondary hyperparathyroidism (2HPT). The chronic high levels of iPTH cause a worsening of graft function, accompanied by systemic symptoms of hypercalcemia. The only curative therapy is parathyroidectomy (PTX). It remains unclear whether total parathyroidectomy with autotransplantation (TPTX-AT) or subtotal parathyroidectomy (SPTX) lead to better outcomes. AIMS: The aim of this retrospective, single-institution cohort study is to evaluate the rate of persistent or recurrent disease and postoperative calcium/iPTH disturbances in patients treated with TPTX-AT or SPTX for 3HPT. METHODS: A single-center retrospective analysis of 3HPT patients submitted to TPTX-AT or SPTX between 2007–2020 with at least 24 months follow-up was conducted. The outcome parameters included persistence/recurrence of disease, incidence of transitory hypocalcemia, and temporary/permanent hypoparathyroidism. RESULTS: A cohort of 52 patients was analyzed and divided in two groups: 38 (73%) were submitted for TPTX-AT, and 14 patients (27%) were submitted for SPTX. The TPTX-AT population showed lower plasmatic calcium concentrations compared with the SPTX group during the entire follow-up period (p<0.001). There were eight cases (21%) of transitory hypocalcemia in the TPTX-AT group and none in the SPTX group, with p=0.065. Two cases (5%) of temporary hypoparathyroidism occurred in the TPTX-AT group and none in the SPTX group, with p= 0.530. There were no cases of permanent hypoparathyroidism and no cases of persistent disease. No statistical difference was assessed for the recurrence of 3HPT between the TPTX-AT group and the SPTX group (N=1, 3% vs N=1, 7%) (p=0.470). CONCLUSION: No significative difference was registered between the TPTX-AT and SPTX groups in terms of persistence/recurrence of disease, incidence of transitory hypocalcemia, and temporary/permanent hypoparathyroidism. Mean calcium levels iPTH values were statistically lower among the TPTX-AT group compared with the SPTX group while remaining always in the range of normality. Frontiers Media S.A. 2023-11-02 /pmc/articles/PMC10652876/ /pubmed/38027172 http://dx.doi.org/10.3389/fendo.2023.1226917 Text en Copyright © 2023 Casella, Guarneri, Campanile, Adhoute, Gelera and Morandi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Casella, Claudio
Guarneri, Claudio
Campanile, Manuela
Adhoute, Xavier
Gelera, Pier Paolo
Morandi, Riccardo
Surgical treatment of tertiary hyperparathyroidism: does one fit for all?
title Surgical treatment of tertiary hyperparathyroidism: does one fit for all?
title_full Surgical treatment of tertiary hyperparathyroidism: does one fit for all?
title_fullStr Surgical treatment of tertiary hyperparathyroidism: does one fit for all?
title_full_unstemmed Surgical treatment of tertiary hyperparathyroidism: does one fit for all?
title_short Surgical treatment of tertiary hyperparathyroidism: does one fit for all?
title_sort surgical treatment of tertiary hyperparathyroidism: does one fit for all?
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652876/
https://www.ncbi.nlm.nih.gov/pubmed/38027172
http://dx.doi.org/10.3389/fendo.2023.1226917
work_keys_str_mv AT casellaclaudio surgicaltreatmentoftertiaryhyperparathyroidismdoesonefitforall
AT guarnericlaudio surgicaltreatmentoftertiaryhyperparathyroidismdoesonefitforall
AT campanilemanuela surgicaltreatmentoftertiaryhyperparathyroidismdoesonefitforall
AT adhoutexavier surgicaltreatmentoftertiaryhyperparathyroidismdoesonefitforall
AT gelerapierpaolo surgicaltreatmentoftertiaryhyperparathyroidismdoesonefitforall
AT morandiriccardo surgicaltreatmentoftertiaryhyperparathyroidismdoesonefitforall